You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical development of novel small molecule malaria drugs that overcome drug

    SBC: DESIGNMEDIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT

    SBC: Elex Biotech, Inc            Topic: NHLBI

    DESCRIPTION provided by applicant Abstract Current therapies to treat the orphan disease catecholaminergic polymorphic ventricular tachycardia CPVT have potential side effects so severe that hospitalization is required upon treatment initiation and severely exacerbate depression and fatigue in children that already have psychological issues due to this devastating life long life threaten ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Short Instrumented Test of Mobility for Neurological Disorders

    SBC: APDM, INC.            Topic: NICHD

    DESCRIPTION provided by applicant APDM is a young company focused on developing and commercializing professional systems using wearable inertial sensors for monitoring of human movement and movement disorders In Phase I we developed the novel Instrumented Stand and Walk test ISAW using APDMandapos s proprietary Opal movement monitors and Mobility Lab system We validated the ISAW by demon ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Evidenced-based Firefighter Worksite Health and Safety Intervention

    SBC: Odyssey Science Innovations, LLC            Topic: 100

    DESCRIPTION provided by applicant Worksite health promotion is a means to improve employeesandapos lifestyles enhance their wellbeing and increase productivity while reducing healthcare and disability costs However most existing worksite health programs are not evidence based Our company Odyssey Science Innovations LLC was formed by experienced health promotion researchers to take our ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Chitosan Endoluminal Hemostatic Dressing

    SBC: HemCon Medical Technologies Inc            Topic: 400

    DESCRIPTION provided by applicant Perioperative hemorrhage remains the major complication of transurethral and open prostatic surgical procedures Significant blood loss from these procedures causes delayed healing and longer hospitalization which significantly increases the cost of patient care Moreover prolonged urethral catheterization due to significant post operative hematuria is one of ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury

    SBC: Apex Biomedical Company, LLC            Topic: 105

    DESCRIPTION provided by applicant Traumatic brain injury TBI is an acquired neurological disorder that can cause long lasting disability with limited treatment options Therefore preventative strategies must be emphasized in high risk activities to reduce the individual and societal burden of this pervasive injury Bicycle activities account for of all sports related TBI with ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of novel compounds for the treatment of atrial fibrillation

    SBC: Elex Biotech, Inc            Topic: NHLBI

    DESCRIPTION provided by applicant Atrial fibrillation AF is the most prevalent type of cardiac arrhythmia in the developed world affecting million people in the United States alone a number that is expected to double by because of population aging Current pharmacological options are ineffective which may be in part because these drugs fail to target key pathogenic mechanisms Recen ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. CMV Vectored Herpes Simplex Vaccine

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent genital lesions and significantly increasing the risk for other sexually transmitted diseases such a ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid Screening Assay for Novel Epigenetic Drugs

    SBC: NZUMBE INC            Topic: NIEHS

    DESCRIPTION (provided by applicant): A hallmark of virtually every cancer is aberrant epigenetic silencing of vital genes required for a normal cell cycle and genome stability (e.g. MLH1, BRCA1, VHL, p16, etc.). Loss of expression of these tumor suppressorgenes plays a critical role in cancer formation and growth. Thus, targeting this root cause of cancer has significant potential to treat and pot ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government